Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2a randomized observer-blind study of mRNA multivalent seasonal influenza vaccine candidates in adults
2025-522278-35-00Phase 2Completed
- Sponsor
- GSK
- Start
- Sep 2025
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 2
01
Overview
Phase 2, randomised, single-blind trial of mRNA-based multivalent seasonal influenza vaccine candidates and Alpharix in influenza (2 arms), sponsored by GSK. Primary endpoints: Antigen 1 antibody titer at Day 29, Fold increase in antigen 1 antibody titer from Day 1 to Day 29 and 8 more. Started Sep 2025; status: completed.
02
Drugs
mRNA-based multivalent seasonal influenza vaccine candidatesAlpharix
03
Conditions
influenza
Beyond the preview
Go deeper on 2025-522278-35-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-522278-35-00.